Cost And Burden Of Poor Anticoagulation Control With Vitamin K Antagonists In Patients With Nonvalvular Atrial Fibrillation In Spain

Introduction and objectives: The aim of this analysis was to evaluate the burden and cost of complications due to poor anticoagulation control in patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin K antagonists (VKA) in Spain.Methods: An analytical model was used to estimate annual differences in ischemic stroke, major bleeding, deaths, costs, and potential years of life lost between patients with poor anticoagulation control (time in therapeutic range < 65%) and adequate control (time in therapeutic range >= 65%) with a 1-year time horizon. Information on the target population (patients >= 65 years), event rates, and costs were obtained from national sources. Direct costs in euros (2018) were included from the perspective of the national health system (NHS) and direct and indirect costs from the societal perspective. A sensitivity analysis was performed with post-hoc data from the SPORTIF III/V trials.Results: We analyzed a hypothetical cohort of 594 855 patients, 48.3% with poor anticoagulation control, with an increase of 2321 ischemic strokes, 2236 major bleeding events and 14 463 deaths, and an annual incremental cost between (sic)29 578 306 from the NHS perspective and (sic)75 737 451 from the societal perspective. The annual impact of mortality was 170 502 potential years of life lost. The results of the sensitivity analysis showed that the annual cost would reach (sic)97 787 873 from the societal perspective.Conclusions: Poor anticoagulation control with AVK has a strong impact on loss of health and on increased spending for the NHS. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.